We report the results from a post hoc analysis of a 5-week dose optimization phase from a large randomized , placebo-controlled , multicenter 40-week study ( 9-week double-blind dose confirmation phase , 5-week open-label dose optimization phase , and 26-week double-blind maintenance of effect phase ) .